Millions of people around the world are living with emphysema, a condition that is chronic and severely impacts quality of life. Many people do not respond well to current medical treatments or are not eligible for major surgery such as lung volume reduction or lung transplantation. Spiration’s minimally invasive IBV® Valve System may improve quality of life for people living with this debilitating condition.

Spiration, Inc. is committed to improving quality of life for patients with acute and chronic conditions of the lung through the development of novel therapies. A U.S. pivotal trial to evaluate safety and effectiveness of the IBV Valve System for the treatment of severe emphysema is currently enrolling patients. An ongoing European clinical study also continues to enroll.